Stocktoria
Indivior Pharmaceuticals, Inc. INDV
Indivior Pharmaceuticals, Inc. (INDV) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $1.2B at a 16.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.33 — elevated (above the −1.78 line — aggressive-accounting signals worth a closer look) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-18 | Barclays | Overweight (init) |
| 2026-01-12 | HC Wainwright & Co. | Buy (main) |
| 2025-10-31 | Piper Sandler | Overweight (reit) |
| 2025-10-30 | HC Wainwright & Co. | Buy (main) |
| 2025-08-27 | Craig-Hallum | Buy (main) |
| 2025-08-06 | HC Wainwright & Co. | Buy (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | -0.218 |
| Retained earnings / assets | -0.202 |
| EBIT / assets | 0.218 |
| Equity / liabilities | -0.075 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| INDV | Indivior Pharmaceuticals, Inc. | 4/9 | -0.7 | 24.3 | +4.3% |
| NSRX | Nasus Pharma Ltd | 3/9 | -13.82 | — | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | 5/9 | 3.97 | 26.6 | +27.4% |
| PBH | Prestige Consumer Healthcare Inc. | 5/9 | 4.04 | 12.3 | -4.3% |
| ACAD | ACADIA PHARMACEUTICALS INC | 4/9 | 3.79 | 11.1 | +11.9% |
| ALKS | Alkermes plc. | 5/9 | 6.24 | 38 | -5.2% |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | 3/9 | -1.18 | — | +432.1% |
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
FAQ
Is INDV financially healthy?
Indivior Pharmaceuticals, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does INDV pay a dividend?
No, Indivior Pharmaceuticals, Inc. does not currently pay a dividend.
How profitable is INDV?
In FY2025, Indivior Pharmaceuticals, Inc. had a net margin of 16.9%.
What is INDV's P/E ratio?
Indivior Pharmaceuticals, Inc.'s trailing price-to-earnings (P/E) ratio is about 24.3×, based on its latest annual earnings.
What is the analyst price target for INDV?
The average Wall-Street price target for Indivior Pharmaceuticals, Inc. is $50.83, about 31.3% above the recent price, from 6 analysts (consensus: strong buy).
Is INDV a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Indivior Pharmaceuticals, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone, a P/E of about 24.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.